Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/3196265

In Collections

This item can be found in the following collections:

Laar, S.A. van; Boer, M.G.J. de; Gombert-Handoko, K.B.; Guchelaar, H.J.; Zwaveling, J.; LUMC-Covid-19 Res grp (2021)

Liver and kidney function in patients with Covid-19 treated with remdesivir

Article / Letter to editor
For the treatment of Covid-19 patients with remdesivir, poor renal and liver function were both exclusion criteria in randomized clinical trials and contraindication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal and liver functions of Covid-19 103 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met randomized clinical trial exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate >10 mL/min/1.73m(2). Also, 25 and 35% had increased alanine transaminase and aspartate transaminase levels, respectively. However, serious adverse events were limited. Therefore, based on these preliminary results, contraindications based on kidney and liver function should not be absolute for remdesivir treatment in patients with Covid-19 if these functions are monitored regularly. A larger patient cohort is...Show moreFor the treatment of Covid-19 patients with remdesivir, poor renal and liver function were both exclusion criteria in randomized clinical trials and contraindication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal and liver functions of Covid-19 103 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met randomized clinical trial exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate >10 mL/min/1.73m(2). Also, 25 and 35% had increased alanine transaminase and aspartate transaminase levels, respectively. However, serious adverse events were limited. Therefore, based on these preliminary results, contraindications based on kidney and liver function should not be absolute for remdesivir treatment in patients with Covid-19 if these functions are monitored regularly. A larger patient cohort is warranted to confirm our results.Show less
adverse events
Covid-19
liver function
remdesivir
renal function
All authors
Laar, S.A. van; Boer, M.G.J. de; Gombert-Handoko, K.B.; Guchelaar, H.J.; Zwaveling, J.; LUMC-Covid-19 Res grp
Date
2021-05-04
Journal
British Journal of Clinical Pharmacology
Volume
87
Issue
11
Pages
4450 - 4454
DOI
doi:10.1111/bcp.14831
Link
https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14831